by Raynovich Rod | Mar 19, 2023 | 2024-25 Life Science Portfolios, Macro
Update-2 3/24..12;15p ..Biopharma and healthcare stocks rally. Update over weekend. ABBV AMGN BIIB GILD REGN VRTX and UNH and Medtech ISRG MDT…small caps EVH PACB. Update-1 3/22…Away from FEDspeak”. We believe that sm aller cap life science stocks...
by Raynovich Rod | Feb 20, 2023 | 2024-25 Life Science Portfolios
SMID Life Science Stocks: Investor or Trader? Despite choppy trading there is an upward tilt to life science stocks since 9/26/22 lows. Three stocks are strong holds: EVH,HOLX and QDEL. Can gene therapy break through in 2023? Our SMID (small and mid) life science...
by Raynovich Rod | Feb 5, 2023 | 2024-25 Life Science Portfolios
Update-2 2/17…QDEL beats on earnings and revenue of $3.37B. EPS of $13.80.Business combination with Ortho still in flux. Stock looks good on technical basis with accumulation. Good value with P/S 1.97, PE is 5.42 and P/FCF 6.45. Recommendation is a...
by Raynovich Rod | Nov 15, 2022 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio
Update-1 11/18…Healthcare stocks had a good week with the XLV up almost 1% to $134 despite choppiness. We are still facing MACRO headwinds and the FED so stay cautious. There was good tape action in mid-cap biopharmas. Medtech is looking better with the IHI up...
by Rod Raynovich | Nov 6, 2022 | Biopharmaceuticals
Update-1 Nov. 8..Volatile election day favors the bulls. IBB and XBI both up over 1%. TSY yields down and dollar down. UNH up 1.48%, Junior metals are hot with gold and silver. Crypto spat rattles markets. Amgen (AMGN) leads the way up over 5% to $290 level a record...
by Raynovich Rod | Dec 21, 2021 | 2024-25 Life Science Portfolios, Biopharmaceuticals
Update-1 12/27 Strong rally day with record closes S&P up 1.38%, NAZ up 1.39%. Megacaps rule AAPL,FB,GOOG, MSFT. Strongest sectors energy and tech. Santa Claus rally is finally here. Retail sales soar with strong consumer. Healthcare up 1.05% to $140 handle but...
by Raynovich Rod | Nov 28, 2021 | 2024-25 Life Science Portfolios, Biopharmaceuticals
Update=3 12/3…Another whipsaw day if you are in Tech stocks (Docusign?) or small cap growth. Blame profit taking ,omicron or tough taper talk. But large cap biopharma held up well: ABBV ABT BMY PFE UNH VRTX etc., but not the IBB – you have to be a stock...
by Raynovich Rod | Nov 22, 2021 | 2024-25 Life Science Portfolios, Biopharmaceuticals
Update-2 11/29 …New Rule- after four downgrades at new lows a stock is a buy. VRTX up over 4% today to $191.5. Is an upgrade coming before or after JPMorgan Healthcare? Update-1 11/23/21… Large cap glam techs stocks take a hit in an another sector...
by Raynovich Rod | Nov 7, 2021 | 2024-25 Life Science Portfolios, Biopharmaceuticals, Macro
11/9…at close..NASDAQ lower by 0.6% after 12 day win streak. IBB down 1.34% coinciding with Biden drug pricing proposal? Large caps mixed but no sell-off. Sold my ARKG and XBI trades at about 3% profit. Vaccine stocks weak. Mid-cap focus stocks weak. Mid-cap...
by Raynovich Rod | Oct 25, 2021 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio
Update-3 11am 10/28 Rally Time! NAZDAQ up 1.22% to 15422. This rally could be signaling Biden getting his economic bill approved without Medicare Drug legislation and less onerous taxes. We’ll see. Apparently all new benefits in the bill are paid for?!...
